Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Stocks | Futures | Watchlist | More
or

Nevro Corp (NVRO)

Nevro Corp (NVRO)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 2,863,889
  • Shares Outstanding, K 31,821
  • Annual Sales, $ 390,260 K
  • Annual Income, $ -103,690 K
  • 60-Month Beta 0.55
  • Price/Sales 7.77
  • Price/Cash Flow N/A
  • Price/Book 13.66

Analyst Rating / Earnings Estimates

Current Rating
See More
Moderate Buy
Based on 13 analysts offering recommendations.
Earnings Estimates - Current Qtr 03/31/20
See More
  • Average Estimate -0.79
  • Number of Estimates 7
  • High Estimate -0.61
  • Low Estimate -1.06
  • Prior Year -1.45
  • Growth Rate Est. (year over year) +45.52%

Price Performance

See More
Period Period Low Period High Performance
1-Month
65.05 +51.25%
on 03/23/20
136.68 -28.01%
on 03/04/20
-31.76 (-24.40%)
since 02/28/20
3-Month
65.05 +51.25%
on 03/23/20
148.05 -33.54%
on 02/26/20
-17.70 (-15.25%)
since 12/27/19
52-Week
54.00 +82.20%
on 05/10/19
148.05 -33.54%
on 02/26/20
+35.88 (+57.40%)
since 03/29/19

Most Recent Stories

More News
Why Is Nevro (NVRO) Down 34.3% Since Last Earnings Report?

Nevro (NVRO) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

NVRO : 98.39 (+9.32%)
Watch for Nevro Corp to Potentially Rebound After Falling 4.61% Yesterday

Nevro Corp (NYSE:NVRO) traded in a range yesterday that spanned from a low of $94.29 to a high of $104.97. Yesterday, the shares fell 4.6%, which took the trading range below the 3-day low of $95.03...

NVRO : 98.39 (+9.32%)
Nevro (NVRO): Strong Industry, Solid Earnings Estimate Revisions

Nevro (NVRO) has seen solid earnings estimate revision activity over the past month, and belongs to a strong industry as well.

NVRO : 98.39 (+9.32%)
Nevro and Stimwave Reach Worldwide Settlement in Patent Infringement Lawsuit: Stimwave Agrees to a Permanent Injunction

Nevro Corp. (NYSE: NVRO), a global medical device company that is providing innovative, evidence-based solutions for the treatment of chronic pain, today announced the settlement of its patent infringement...

NVRO : 98.39 (+9.32%)
Nevro Files Lawsuit for Patent Infringement Against Nalu Medical in the U.S.

Nevro Corp. (NYSE: NVRO), a global medical device company that is providing innovative, evidence-based solutions for the treatment of chronic pain, today announced that it has filed a lawsuit for patent...

NVRO : 98.39 (+9.32%)
Nevro (NVRO) Q4 Loss Narrower Than Expected, Revenues Up Y/Y

Nevro (NVRO) sees strong segmental contributions in Q4.

SYK : 162.96 (+2.35%)
ARAY : 1.7400 (+4.19%)
IDXX : 241.02 (+4.00%)
NVRO : 98.39 (+9.32%)
Nevro (NVRO) Reports Q4 Loss, Tops Revenue Estimates

Nevro (NVRO) delivered earnings and revenue surprises of 29.03% and 3.20%, respectively, for the quarter ended December 2019. Do the numbers hold clues to what lies ahead for the stock?

NVRO : 98.39 (+9.32%)
Nevro: 4Q Earnings Snapshot

REDWOOD CITY, Calif. (AP) _ Nevro Corp. (NVRO) on Tuesday reported a loss of $13.7 million in its fourth quarter.

NVRO : 98.39 (+9.32%)
What in Store for Universal Health's (UHS) Q4 Earnings?

Universal Health's (UHS) Q4 results are likely to reflect gains from both its Acute Care and Behavioral Health segments.

UHS : 100.13 (+12.52%)
AMAG : 6.17 (+3.87%)
ADRO : 2.52 (-1.18%)
NVRO : 98.39 (+9.32%)
What's in Store for Patterson Companies' (PDCO) Q3 Earnings?

Patterson Companies (PDCO) expects Animal Health sales to have been soft in fiscal Q3.

ABM : 24.17 (+9.91%)
PDCO : 16.34 (+2.38%)
BURL : 162.53 (+4.30%)
NVRO : 98.39 (+9.32%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 8% Sell with a Weakest short term outlook on maintaining the current direction.

See More Share

Trade NVRO with:

Business Summary

Nevro Corp. is a medical device company. It engages in developing and commercializing a neuromodulation platform for the treatment of chronic pain. The Company provides pain relief to the customers suffering from low back pain and types of chronic pains. Nevro has developed and commercialized the Senza...

See More

Key Turning Points

2nd Resistance Point 106.54
1st Resistance Point 102.47
Last Price 98.39
1st Support Level 91.61
2nd Support Level 84.82

See More

52-Week High 148.05
Fibonacci 61.8% 112.12
Fibonacci 50% 101.03
Last Price 98.39
Fibonacci 38.2% 89.93
52-Week Low 54.00

See More

Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.
Get Streaming Chart Updates
Switch your Site Preferences
to Interactive Chart
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar